bioAffinity Technologies (BIAFW) Stock Analysis

What bioAffinity Technologies does

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Key metrics

ETFs linked to BIAFW

Broad-market and Healthcare sector ETFs an investor holding bioAffinity Technologies is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how BIAFW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for bioAffinity Technologies?

bioAffinity Technologies trades under the ticker BIAFW on NASDAQ.

Which exchange is BIAFW listed on?

BIAFW is listed on NASDAQ.

What sector does bioAffinity Technologies operate in?

bioAffinity Technologies is classified in the Healthcare sector (Medical - Diagnostics & Research industry).

How can PortView help analyze BIAFW in a portfolio?

PortView shows BIAFW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.